Thus, our findings implicate Tip60 as a critical mediator of EE-induced benefits and provide new insights into HAT based drug design that could compliment non-invasive behavioral strategies for early therapeutic intervention of cognitive disorders. The gene discussed is KAT5; the disease is cognitive disorder.